Hemoglobin Electrophoresis and HbA2 in the Endurance-Athlete Microcytic-Anemia Workup: Why the Iron-Loading Reflex Fails the Thalassemia-Trait Athlete, the Paired MCV-Ferritin-TSAT-HbA2 Read That Separates the Two Presentations, and the SOAP Structure That Carries the Read Into the Coordinated Referral

A 24-year-old collegiate cross-country runner of Greek ancestry presents to the sports RD in week three of the base phase with a chief complaint of legs that read heavy on the tempo intervals, a resting heart rate that has crept from her seasonal baseline of 48 to a morning number of 56 across the last two weeks, and a coach note flagging that her 6-kilometer time-trial pace regressed by 12 seconds per kilometer against her spring baseline. Her intake CBC returned two days ago with a hemoglobin of 11.2 g/dL against a female reference of 12.0 to 15.5, a hematocrit of 34.1 percent, an MCV of 68 fL against a reference of 80 to 100, and an RDW of 14.8 percent. The primary care nurse practitioner read the panel as "iron deficiency anemia, likely training-associated," ordered a ferritin, started her on ferrous sulfate 325 mg three times daily, and queued a repeat CBC in eight weeks.

The ferritin returned yesterday at 78 ng/mL. TSAT came back at 32 percent. Both values sit comfortably inside the reference ranges the RD would use to rule iron deficiency in. The nurse practitioner has not seen the ferritin yet, and the athlete has been on the ferrous sulfate for four days.

The reflex that starts iron on an endurance athlete with a microcytic anemia is the correct reflex the majority of the time. Iron deficiency is the most common cause of microcytic anemia in the female endurance-athlete population, foot-strike hemolysis and menstrual losses compound the risk, and the ferritin-plus-TSAT screen catches the presentation cleanly when it fits the pattern. The reflex fails on the minority of presentations where the microcytosis is not driven by iron status. The most important of those minority presentations for the sports RD is beta-thalassemia trait, and the fingerprint of beta-thalassemia trait sits on the hemoglobin electrophoresis panel the ferritin-plus-TSAT screen does not include.

This is the electrophoresis and HbA2 interpretation guide: what the electrophoresis actually measures and why HbA2 elevation above 3.5 percent is the beta-thalassemia-trait fingerprint the CBC and iron panel together cannot see, why endurance athletes from Mediterranean, Middle Eastern, Southeast Asian, African, and Southern Chinese ancestry populations sit at 3 to 10 percent carrier prevalence and are systematically underscreened, the paired MCV-ferritin-TSAT-HbA2 interpretive framework that separates iron deficiency from thalassemia trait from the compound presentation, the four intake presentations that should trigger the electrophoresis referral, and the SOAP documentation structure that carries the paired-marker read into the coordinated hematology conversation before the wrong intervention starts.

What Hemoglobin Electrophoresis Actually Measures

Adult hemoglobin is a tetramer of four globin chains — normally two alpha and two beta — with an iron-containing heme group at each chain. In the healthy adult, roughly 95 to 98 percent of circulating hemoglobin is HbA (alpha2-beta2), 2 to 3.5 percent is HbA2 (alpha2-delta2), and less than 1 percent is HbF (alpha2-gamma2, the fetal hemoglobin that dominates before birth and declines through the first year of life). Hemoglobin electrophoresis separates these globin-chain compositions by charge and size — historically on cellulose acetate or citrate agar gel, currently on capillary zone electrophoresis or high-performance liquid chromatography in most reference labs — and returns a quantitative percentage breakdown of the hemoglobin species present in the sample.

The two panel outputs that carry the most diagnostic weight for the sports RD are HbA2 quantification and the presence or absence of variant hemoglobins (HbS, HbC, HbE, HbD, HbH, and others).

HbA2 above 3.5 percent is the biochemical fingerprint of beta-thalassemia trait. The mechanism is straightforward: in the heterozygous carrier of a beta-globin gene mutation, beta-chain production is reduced, the alpha chains that would normally pair with them go looking for alternative partners, and the delta-chain-containing HbA2 fraction rises to compensate. The elevation is quantitative, reproducible, and diagnostic in the absence of concurrent iron deficiency (iron deficiency can artificially lower HbA2 into the reference range and mask the trait, which is a critical read for the paired interpretive framework below).

Variant hemoglobin bands identify sickle cell trait (HbAS), hemoglobin C trait, hemoglobin E trait (common in Southeast Asian ancestry populations), and other structural variants. The sports RD is not the primary manager of these findings, but the panel identifies them alongside the HbA2 quantification and the coordinated hematology referral becomes the correct next step for any variant hemoglobin flagged.

Alpha-thalassemia trait is the harder read on standard electrophoresis. Alpha-thalassemia trait carriers do not typically show an HbA2 elevation because the alpha-chain reduction affects HbA, HbA2, and HbF proportionally. The electrophoresis in alpha-thalassemia trait usually returns as normal, and the diagnosis rests on the paired presentation of microcytic anemia with adequate iron stores and a normal HbA2, sometimes confirmed by molecular alpha-globin genotyping. Alpha-thalassemia trait is most prevalent in Southeast Asian, African, and Middle Eastern ancestry populations.

Why the Endurance-Athlete Population Is Underscreened

Beta-thalassemia trait and alpha-thalassemia trait carrier prevalence in the general U.S. population sits at roughly 0.5 to 1 percent, driven mostly by descent from historically endemic regions. In specific ancestry populations that are heavily represented in endurance sports, carrier prevalence is much higher: 3 to 10 percent in Mediterranean-descent populations (Greek, Italian, Cypriot, Sardinian), 5 to 15 percent in Middle Eastern populations, 3 to 8 percent in Southeast Asian populations, and 5 to 25 percent in Southern Chinese and West African populations depending on the specific regional ancestry. The endurance-sports population — collegiate distance running, triathlon, road cycling, cross-country skiing — draws heavily from these ancestry backgrounds, and the intake screen that does not ask the ancestry question systematically misses the athletes who should be first in line for the electrophoresis referral.

The misdiagnosis pattern is reproducible: microcytic anemia is discovered on intake CBC, iron is started reflexively without waiting for the ferritin-plus-TSAT panel, ferritin returns within reference and the iron is continued anyway on the theory that "tissue iron" is depleted, the eight-week repeat CBC returns essentially unchanged, iron dose is escalated or intravenous iron is discussed, and the athlete is queued for further workup only after the second or third failed iron intervention. The season is halfway over. The correct read would have been the paired ferritin-TSAT-HbA2 panel at the initial workup, with the electrophoresis triggered by the ancestry-plus-microcytosis pattern.

The iron-overload risk is not hypothetical. Beta-thalassemia trait carriers absorb dietary iron slightly more efficiently than non-carriers, and iron loading in a carrier with an already-adequate ferritin can push the athlete into the 300-to-500 ng/mL ferritin band that carries early markers of iron-loading physiology. Repeat iron loading across multiple seasons compounds the risk. The primary care system that started the ferrous sulfate without the electrophoresis is not tracking the ferritin trajectory across seasons, and the athlete's cumulative iron exposure sits at the RD's monitoring interface.

The Paired MCV-Ferritin-TSAT-HbA2 Interpretive Framework

My interpretive framework for the endurance-athlete microcytic-anemia presentation, holding the paired-marker discipline at the initial workup rather than after a failed iron trial:

Low MCV, low ferritin (below 30 ng/mL), low TSAT (below 20 percent), normal HbA2. Classic iron-deficiency anemia. Oral iron trial at 40 to 60 mg elemental iron every other day (the alternate-day dosing carries better absorption efficiency than daily dosing per the Stoffel et al. mechanism-of-hepcidin literature), reassessment at eight weeks with paired ferritin and CBC. Ninety percent of the endurance-athlete microcytic presentations fall in this bucket.

Low MCV, ferritin above 30 to 40 ng/mL, TSAT within reference, HbA2 above 3.5 percent. Beta-thalassemia trait, uncomplicated by iron deficiency. Do not start iron. Coordinated hematology referral for confirmation and family counseling. The microcytic anemia is the athlete's genetic baseline, not a nutritional deficit, and the sports RD's role shifts from correction to monitoring: baseline hemoglobin will typically sit in the 10.5 to 12.5 g/dL range for female carriers and 11.5 to 13.5 g/dL for male carriers, oxygen-carrying capacity is functionally compensated across most training loads, and the performance ceiling under load is set closer to VO2max efficiency than to hemoglobin mass in this population.

Low MCV, low ferritin, low TSAT, HbA2 above 3.5 percent. Compound presentation — iron deficiency layered on top of beta-thalassemia trait. This is the pattern where the electrophoresis at the initial workup changes the entire intervention arc. Treat the iron deficiency (alternate-day oral iron, eight-week reassessment) but with the explicit understanding that the CBC will not fully normalize — the target is restoration of ferritin above 50 ng/mL and the resolution of the iron-deficiency layer, not normalization of the hemoglobin or MCV to reference. The residual anemia is the thalassemia-trait baseline. The coordinated hematology referral remains warranted for the thalassemia-trait confirmation.

Low MCV, low ferritin, low TSAT, HbA2 within reference (2 to 3.5 percent) but on the high side of reference (3.0 to 3.5). Ambiguous read. Iron deficiency can artificially lower HbA2 into the reference range and mask an underlying beta-thalassemia trait. If the ancestry and family history support the differential, repeat the HbA2 quantification after eight weeks of iron correction and reassessment against the post-correction ferritin. HbA2 that rises above 3.5 percent on the post-correction repeat draw is the delayed thalassemia-trait diagnosis.

Low MCV, ferritin within reference, TSAT within reference, HbA2 within reference, ancestry consistent with alpha-thalassemia carrier populations. Consider alpha-thalassemia trait as the working differential. Hematology referral for molecular alpha-globin genotyping is the confirmatory pathway. Do not start iron. Baseline anemia is the athlete's genetic pattern and the monitoring frame is the same as beta-thalassemia trait.

The clinical rule I hold at the intake: the initial workup for microcytic anemia in an endurance athlete of Mediterranean, Middle Eastern, Southeast Asian, African, or Southern Chinese ancestry should include the electrophoresis at the first draw, not after a failed iron trial. The additional lab cost is $60 to $120 depending on the reference lab. The cost of an incorrect eight-week iron trial in a thalassemia-trait athlete is the season.

The Four Intake Presentations That Trigger the Electrophoresis Referral

Any endurance athlete of Mediterranean, Middle Eastern, Southeast Asian, African, or Southern Chinese ancestry presenting with a microcytic anemia (MCV below 80 fL, hemoglobin below sex-specific reference), regardless of the initial ferritin read. The ancestry-plus-microcytosis pattern is the highest-yield trigger in the sports RD's practice. Add the electrophoresis to the initial paired ferritin-TSAT-CBC draw and read all three together.

Any endurance athlete presenting with a microcytic anemia that has not resolved after an eight-to-twelve-week oral iron trial, regardless of ancestry. The failed iron trial is the empirical trigger. Order the electrophoresis before escalating to intravenous iron or a second oral iron cycle.

Any endurance athlete with a family history of thalassemia, sickle cell disease, or unexplained anemia in a first-degree relative. The family-history trigger overrides the ancestry heuristic. The genetic pattern travels through the family, and the intake questionnaire that captures the family history is doing the screening the ancestry-alone read cannot.

Any athlete presenting for a pre-conception or pregnancy sports-nutrition workup with a personal or family history that raises the thalassemia-trait differential. The obstetric implications of paired-carrier partnerships are meaningful — two carriers of the same trait produce a 25 percent risk of the homozygous disease state in each pregnancy — and the coordinated hematology-plus-obstetrics referral for genetic counseling is the appropriate next step regardless of the current CBC read.

The SOAP Documentation

My structure on the presenting vignette above reads: "Twenty-four-year-old female collegiate distance runner of Greek ancestry, three-week presentation of subjective heavy-legs on tempo intervals with a 12-second-per-kilometer regression on 6K time trial and a resting heart rate increase from seasonal baseline of 48 to 56. Intake CBC hemoglobin 11.2 g/dL, hematocrit 34.1 percent, MCV 68 fL, RDW 14.8 percent. Ferritin 78 ng/mL, TSAT 32 percent — both within reference and inconsistent with the iron-deficiency-anemia interpretation that initiated the ferrous sulfate prescription four days ago. Ancestry, microcytic-anemia pattern, and iron-adequate ferritin together consistent with a beta-thalassemia-trait differential the standard microcytic-anemia workup did not screen for. Ferrous sulfate 325 mg three times daily held pending the electrophoresis and hematology consultation given the iron-overload risk in an already-iron-adequate carrier phenotype. Assessment: probable beta-thalassemia trait presenting as microcytic anemia in an iron-adequate endurance athlete; the training-load-associated fatigue is a separable question that will be re-worked once the hematology read is in hand. Plan: coordinated referral to hematology for hemoglobin electrophoresis with HbA2 quantification, held iron prescription communicated to prescribing NP with rationale, sports-medicine physician looped for training-load review pending the hematology confirmation, reassessment at four and twelve weeks post-electrophoresis result."

The assessment line names the pattern explicitly and cites the paired ferritin-plus-TSAT read that closed the iron-deficiency differential rather than opening it. The referral letter carries the paired-marker interpretive framework so the hematologist receives a diagnostic starting point rather than an open question about a microcytic anemia in a runner.

The Reassessment Loop

At the twelve-week paired-panel redraw following a confirmed thalassemia-trait diagnosis:

Ferritin stable within the 50-to-150 ng/mL range, hemoglobin at the athlete's confirmed thalassemia-trait baseline, symptoms attributed to the initial presentation resolved or attributable to a separable etiology (training-load, sleep, nutrition adequacy, hydration). Document the thalassemia-trait baseline on the athlete's chart for future intake reference, avoid the reflex iron prescription on any future microcytic-anemia read, and shift the monitoring frame to ferritin trajectory across seasons with an eye toward the 300 ng/mL ceiling and the iron-overload risk.

Ferritin trending upward past 200 ng/mL in an athlete on any iron-containing multivitamin or supplement stack. Audit the supplement stack. The thalassemia-trait carrier does not need routine iron supplementation, and the multivitamin that carries 18 mg elemental iron per serving is contraindicated at chronic use. Substitute an iron-free multivitamin, hold the ferritin trajectory below the 300 ng/mL ceiling, and coordinate with the primary care and hematology teams on the monitoring cadence.

Persistent unexplained anemia beyond the confirmed thalassemia-trait baseline, or a hemoglobin drop below the athlete's post-workup baseline of 3 or more g/dL. The differential expands to include compound presentations (iron deficiency layered on the trait, foot-strike hemolysis, occult GI blood loss, disordered eating with under-fueling driving a secondary anemia). The coordinated workup runs on the paired-marker discipline that carried the initial presentation, with the sports RD's dietary intake and menstrual-cycle data feeding the differential.

Why the Electrophoresis-Included Workup Changes the Referral Conversation

The sports RD who arrives at the coordinated referral with the paired ferritin-TSAT-electrophoresis read is having a different conversation with the primary care physician or hematologist than the sports RD who arrives with "the athlete has a microcytic anemia and the iron trial did not resolve it." A referral letter that reads "microcytic anemia in a Greek-ancestry female endurance athlete with ferritin 78 ng/mL, TSAT 32 percent, HbA2 4.8 percent on electrophoresis, consistent with beta-thalassemia trait, iron prescription held pending your confirmation, coordinated monitoring plan attached" hands the specialist a diagnostic starting point that assumes the nutritional workup has already run and asks the specialist to confirm or extend rather than repeat.

The athlete does not spend eight weeks on the wrong intervention. The season is not lost to a missed differential. The chart carries the thalassemia-trait diagnosis forward as a permanent intake reference that prevents the reflex iron prescription on every future microcytic-anemia read across the athlete's career.

Where Calsanova Fits

The paired ferritin-TSAT-electrophoresis workup depends on the intake carrying the ancestry-plus-family-history data at the same visit as the initial CBC read, the interpretive framework that separates iron-deficiency anemia from thalassemia trait from the compound presentation, the SOAP template that carries the paired-marker read into the coordinated referral letter, the flag that catches an iron prescription about to start on an iron-adequate athlete before the intervention arc begins, and the reassessment schedule that tracks ferritin trajectory across seasons against the iron-overload ceiling. Calsanova's clinical intake carries the ancestry and family-history capture at the initial visit, the paired ferritin-TSAT-electrophoresis interpretive framework built into the lab-integration module, the SOAP template that pre-populates the paired-marker read and the thalassemia-trait-versus-iron-deficiency differential, the medication-and-supplement audit that flags iron-containing products in a confirmed carrier chart, and the coordinated-referral module that generates the paired referral letter with the electrophoresis-included workup attached to the hematology consult.

Ready to move your sports-nutrition intake workflow into a purpose-built clinical system? [Try Calsanova free for 30 days](/signup?role=dietitian) — no credit card, HIPAA-ready from day one, and the paired ferritin-TSAT-electrophoresis workup runs automatically with the ancestry-and-family-history capture, the athlete-adjusted interpretive framework, and the coordinated-referral module pre-populated against the initial CBC read.